Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 2 106 / https://doi.org/10.3332/ecancer.2008.106

Short Communication

SPECT/CT 90Y-Bremsstrahlung images for dosimetry during therapy

Background: the characteristics of 90Y, suitable for therapy, are denoted by the lack of γ-emission. Alternative methods, using analogues labelled with 111In or 86Y, are generally applied to image 90Y-conjugates, with some inevitable drawbacks. New generation SPECT/CT image systems offer improved Bremsstrahlung images. The intent of this brief communication is to show that high quality 90Y-Bremsstrahlung SPECT-CT images can be obtained, allowing the biodistribution of pure β-emitter therapeutical agents to be evaluated, also during the course of therapy.

Methods: the hybrid system Siemens Symbia-T2 was used for the acquisition of images of a patient given 1.7 GBq of 90Y-DOTATATE. The following parameters were set for SPECT: 80 (50%) and 120 (30%) keV energy windows; medium energy collimators; 128 x 128 matrix, 64 projections (40s/step). Low-dose CT was acquired (80 mAs) for attenuation correction. Images were reconstructed with the OSEM 3D-Fast algorithm.

Results: post-therapy SPECT-CT 90Y-Bremsstrahlung images of a patient undergoing receptor peptide radionuclide therapy are presented. 90Y-Bremsstrahlung images obtained are suitable for tumour and normal organ dosimetry, providing detailed information on biodistribution, comparable to 111In-diagnostic images.

Conclusions: the improved Bremsstrahlung images means that the diagnostic examinations can be used for patient recruitment and that dosimetry evaluation can be restricted only to treated patients. This could avoid the need for a different radionuclide or isotope to mimic therapy. The clinical impact might be notable, as dosimetry and toxicity information are essential in radionuclide therapy, especially in patients with risk factors.

Loading Article Metrics ... Please wait

Related articles

Research: Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy

Abstract | Full Article | PDF Published: 06 Jun 2019 / https://doi.org/10.3332/ecancer.2019.934

Case Report: Two cases of gastric mucosa-associated lymphoid tissue (MALT) lymphoma masquerading as follicular gastritis

Abstract | Full Article | PDF Published: 03 Jun 2019 / https://doi.org/10.3332/ecancer.2019.933

Conference Report: Highlights from the 13th African Continental Meeting of the International Society of Paediatric Oncology (SIOP), 6–9 March 2019, Cairo, Egypt

Abstract | Full Article | PDF Published: 28 May 2019 / https://doi.org/10.3332/ecancer.2019.932

Case Report: Surgical treatment in oligometastatic breast cancer

Abstract | Full Article | PDF Published: 20 May 2019 / https://doi.org/10.3332/ecancer.2019.931

Case Report: Chemotherapy and anti-HER2 therapy in metastatic breast cancer in pregnancy followed by surgical treatment

Abstract | Full Article | PDF | Spanish Published: 14 May 2019 / https://doi.org/10.3332/ecancer.2019.930



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation